Tag Archives: Hanmi Pharmaceuticals

Roche Licenses Muscle-Preservation AOM from Hanmi; Foundayo UK Launch; Lilly Initiates Second Ph3 Brenipatide MDD Study; Lexicon Receives Third LX9851 Milestone Payment; Biomea Completes COVALENT-211 Enrollment

A series of cardiometabolic-related news items has been observed from Roche/Hanmi, Lilly, Lexicon, and Biomea Fusion. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Biomea Ph2 T2DM Results; AZ Ph3 Baxdrostat Data; Ionis 2025 Innovation Day; New Hanmi Ph2 Triple Agonist Study; MannKind Completes scPharmaceuticals Acquisition; Fractyl Health Preclinical Gene Therapy Data

A series of cardiometabolic-related news items has been observed from Biomea Fusion, AstraZeneca, Ionis Pharmaceuticals, Hanmi Pharmaceuticals, Fractyl Health, and MannKind. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Alnylam/Roche Initiate Zilebesiran CVOT; Hanmi Files Obesity IND; Sagimet Ph1 MASH Study

Three cardiometabolic-related news items have been observed: Alnylam/Roche dosed the first patient in the Ph3 ZENITH CVOT study evaluating zilebesiran in uHTN (view press release); Hanmi Pharmaceuticals filed an IND for its muscle-sparing obesity candidate (view press release); and Sagimet Biosciences dosed the first participants in its Ph1 study of denifanstat + resmetirom (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here